Latest news with #NIO
Yahoo
2 hours ago
- Business
- Yahoo
NIO pops on SUV demand, Rivian downgrade, McGraw Hill IPO
Yahoo Finance anchor Julie Hyman examines some of the top stories of the trading day on Yahoo Finance's Market Minute. NIO (NIO) stock rises on demand for the Chinese electric vehicle (EV) maker's new SUV after Morgan Stanley analysts reported 30,000 to 35,000 preorders for NIO's upcoming vehicle. Rivian (RIVN) stock is under pressure after Guggenheim analysts downgraded the stock to Hold from Buy on headwinds from Trump's tax legislation. McGraw Hill is set to raise $537 million in its initial public offering (IPO), with shares expected to be priced between $19 and $22. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for your Yahoo! Finance's market minute. Stocks not much changed as investors digest tariff risks and look ahead to the June CPI report on Tuesday. Shares of Chinese EV maker Neo jumping on strong demand for its new SUV. Shares up over 5%, actually over 6% after Morgan Stanley said it saw 30 to 35,000 pre-orders for Neo's upcoming vehicle in the firm's latest channel checks. Meanwhile, Rivian shares falling after getting a downgrade to hold from buy at Guggenheim. The analyst citing the Republican tax bill as a major headwind for the company's long-term growth. And education tech company McGraw Hill looking to raise over $500 million through a US IPO. The company is offering 24.4 million shares currently priced at about $19 to $22 each, giving it a valuation of about $4.2 billion. This would be McGraw Hill's latest attempt to go public after withdrawing applications in 2022 and 2018. And that's your Yahoo! Finance market minute. Scan the QR code below to track the best and worst performing stocks of the session. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)
Business Standard
7 hours ago
- Automotive
- Business Standard
Leapfrogging the world: China's rise in EVs, green energy and biotech
In the global race for technological supremacy, the spotlight has long fallen on Silicon Valley or Europe's innovation hubs. But behind the scenes, China is not merely catching up, it is rapidly emerging as a global frontrunner, spearheading transformative progress across electric vehicles (EVs), renewables, and biotechnology. Fuelled by state-backed strategies, relentless innovation, and manufacturing muscle, China's ascent is not just changing industries, it is redefining the world's technological future. EV boom: How China became the world's largest electric vehicle market China now controls the world's largest EV market, selling over 11 million units annually and accounting for more than 50 per cent of global EV sales. Companies like BYD, NIO, XPeng, and Li Auto have aggressively expanded beyond Chinese borders, with BYD overtaking Tesla in total global EV sales in 2025. China's dominance in EV exports is equally notable. In 2024, it shipped out 1.2 million EVs—surpassing Japan to become the world's top automobile exporter. Once mocked for low-cost knock-offs, Chinese EVs now compete on both price and advanced tech in Europe, Southeast Asia, and North America. According to Bloomberg, China's EV sales reached 11 million units in 2024, capturing nearly two-thirds of the global market, compared to 17 per cent in Europe and just 7 per cent in the US. In Q1 2025 alone, Chinese EV sales rose 55 per cent to 1.64 million units, outpacing Europe's 28 per cent (574,000) and the US' 18 per cent (301,000). What explains China's electric vehicle dominance? At the heart of China's EV power lies control over battery technology. With 70 per cent of global EV production and two domestic giants, CATL and BYD, supplying 55 per cent of the world's batteries, China enjoys unmatched battery pricing and efficiency. Fierce local competition has driven breakthrough innovations, bringing battery costs below $100/kWh for lithium iron phosphate (LFP) batteries, reaching price parity with combustion engines, a milestone still out of reach in the West. China's vertically integrated supply chain accounts for 75 per cent of lithium-ion battery production, and dominates cobalt/lithium refining and cathode/anode materials. In contrast, European and US supply chains remain fragmented and face 20 per cent higher production costs. Technologies like battery-swap stations and vehicle-to-grid (V2G) integration are giving Chinese EVs a technological and cost advantage. How state strategy fuels China's EV ecosystem Under the 'Made in China 2025' plan, China has built a powerful EV ecosystem through massive subsidies, sustained infrastructure investment, and long-term supply chain planning. It already boasts 20 times more public EV chargers than the US, and four times as many as Europe. China's renewable energy dominance breaks all global records In the renewables sector, China's lead is even more formidable. As of mid-2025, its solar capacity stood at 887 GW, with wind at 521 GW. The country invested $625 billion in clean energy in 2024 alone, according to Reuters. By comparison, the US has just 239 GW of solar, and the EU a combined 540 GW of wind and solar. In 2024, China added 445 GW of new renewables, 60 per cent of global additions. It builds three out of every four solar and wind installations worldwide and is on track to exceed its 2030 emissions targets ahead of schedule. China also manufactures over 80 per cent of the world's solar panels and dominates every stage of the solar and battery supply chain. Economies of scale, vertical integration, and heavy subsidies let Chinese producers outprice global competitors. Chinese biotech: From copycats to cutting-edge drug developers China's biotechnology sector is undergoing a dramatic transformation. Once known for generics, Chinese drugmakers are now innovating at scale. Bloomberg's analysis of Norstella data shows that China had over 1,250 novel drug candidates in 2024, closing in on the US (1,440) and far ahead of the EU. Back in 2015, that number was just 160. Chinese biopharma companies, once burdened with quality concerns, are increasingly earning approvals and partnerships with global regulators and pharma majors. By 2024, Chinese firms accounted for 31 per cent of all innovative drug pipelines globally, second only to the US. Policy reforms and returning scientists reshape Chinese biotech China's shift began in 2015 with sweeping reforms to its drug regulatory framework, accelerating approvals, enforcing global data standards, and encouraging repatriation of overseas-trained researchers. Coupled with the Made in China 2025 strategy, these efforts triggered a biotech investment boom. By 2024, China had overtaken the EU in expedited approvals from the FDA and EMA. Faster drug approvals and global impact Take Legend Biotech's cell therapy for blood cancer—marketed by Johnson & Johnson. It not only outpaced a US-made rival but also secured expedited review in multiple markets. Although Chinese firms still focus on refining existing therapies more than inventing new ones, their innovation pipeline is expanding. Of the world's top 50 companies with the most innovative drug candidates between 2020 and 2024, 20 are Chinese—up from just five in the prior five-year period. Jiangsu Hengrui, once a generic drugmaker, now leads globally in the number of new drug candidates added. Global pharma giants race to license Chinese innovations Western pharma majors are rushing to partner with Chinese firms: > Akeso Inc. licensed its cancer drug to Summit Therapeutics for $500 million upfront, seen as China biotech's 'DeepSeek moment' > Pfizer signed a record $1.2 billion upfront deal in May 2025 with 3SBio Inc. for a cancer therapy > Merck, AstraZeneca, and Roche have all snapped up Chinese drug assets According to DealForma, such high-value licensing deals are growing in both number and value. China's clinical trial edge: speed and scale A key advantage for Chinese biotech is speed. Thanks to vast patient pools and centralised hospitals, trial recruitment in China happens twice as fast as in the US. Lower costs allow companies to run multiple clinical trials simultaneously, boosting success odds. Since 2021, China has led the world in new clinical trial starts, ahead of the US, per GlobalData. However, challenges remain. The FDA still requires multinational data, limiting the use of China-only trials for US approvals. US reacts to China's biotech rise with new policy anxieties As US-China tensions rise, China's biotech progress has drawn concern in Washington. A congressional report warned that the US may cede leadership in another strategic domain. Policymakers are calling for tighter export restrictions and faster domestic drug approval processes. The China model: What makes its rise hard to replicate Across EVs, renewables, and biotechnology, China's strategy follows a clear pattern: centralised industrial planning, global supply chain dominance, technology at scale, and relentless execution speed. For the West, the question is no longer if China can lead in innovation, but how soon, and how far.
Gizmodo
a day ago
- Automotive
- Gizmodo
As Sales Drop, Tesla Makes a Big Gamble on India
Tesla is finally entering India. The all-electric carmaker will open its first showroom in the country on July 15 in Mumbai, marking a long-awaited entry into one of the largest and fastest-growing automotive markets in the world. Invitations to the launch event began circulating on social media late last week. 'Launch Event. Exclusive Invite,' the sleek black cards read. 'Tesla Experience Center BKC.' The event is scheduled to take place from 11:00 a.m. to 12:30 p.m. local time, with guests asked to arrive early. The venue is located in Mumbai's upscale Bandra Kurla Complex. As with most things Tesla, the invitation triggered a storm of reactions online, fervent excitement from fans, and sharp skepticism from critics. And it's no surprise. CEO Elon Musk's company is under enormous pressure, both financially and politically. Tesla's sales have been declining for most of 2025, weighed down by a mix of aging models, intensifying global competition, and self-inflicted political damage. The company's current lineup includes the Model 3 sedan, the Model Y SUV (currently the world's best-selling electric vehicle), the Cybertruck, the Model S luxury sedan, and the Model X SUV. But Tesla hasn't launched a new passenger vehicle in years, and the lineup is beginning to show its age. Meanwhile, legacy automakers and aggressive upstarts have closed the technology gap. General Motors, Ford, Volkswagen, Mercedes-Benz, BYD, NIO, and others are rolling out new electric vehicles at a furious pace, often priced more competitively than Tesla's core offerings. Adding to the pressure is Musk's increasingly polarizing public persona. Once a cult hero for tech progressives and climate advocates, Musk has alienated much of Tesla's original customer base with his far-right political rhetoric and attacks on perceived 'woke' institutions. The company is also facing significant macroeconomic headwinds. In the last three months, Tesla's overall sales have declined by 13.5%. President Donald Trump's trade war has crippled sales in Canada, forcing a desperate, deep price cut on the Model Y. And in the United States, demand for electric vehicles is expected to soften with the expiration of the $7,500 federal tax credit on September 30. Against this tumultuous backdrop, the Indian market couldn't have come at a better time. India is now the third-largest auto market in the world, behind China and the United States. Although EV adoption in India remains low compared to Western countries, the sector is growing fast, fueled by government incentives and a rising urban middle class. Tesla has had its eye on India for years, but repeated attempts to enter the market were blocked by disputes over local manufacturing requirements and high import taxes. That breakthrough finally came in early 2025, after Musk met with Indian Prime Minister Narendra Modi during a state visit to Washington. 'Spoke to @elonmusk and talked about various issues,' Modi posted on X last April. 'We discussed the immense potential for collaboration in the areas of technology and innovation.' Musk responded: 'I am looking forward to visiting India later this year!' It was an honor to speak with PM Modi. I am looking forward to visiting India later this year! — Elon Musk (@elonmusk) April 19, 2025In anticipation of the launch, Tesla created an official account on X, @Tesla_India, posting a single tweet that read 'Coming soon.' Since Tesla does not have a factory in the country, it is expected that vehicles will be imported from its Gigafactory in Shanghai. According to Bloomberg, Tesla has already shipped its first batch of vehicles, mostly Model Y SUVs. That hasn't stopped a wave of anticipation from building. 'Are bookings open?' one user posted on X. Bookings are open? — Nitish Bhatia (@NITISHBHATIA1) July 11, 2025 'Any word on when the first deliveries are?' another asked. 'Finally excited to see Tesla cars on Indian roads,' wrote a third. 'Any owners taking first deliveries, please record and share your thoughts or make a vlog.' Awesome, finally excited to see Tesla cars on Indian roads. Any owners taking first deliveries, please record and share your thoughts or make a vlog. I will be willing to watch such videos as I am curious about the whole Tesla India experience. I'm sure lots of other folks are… — Cybrtsla (@cybrtsla) July 11, 2025 'Finally the most cherished dream of @TeslaClubIN and car enthusiasts like me will end on July 15,' another user said. 'Finally long wait is over,' another added. But skepticism remains. A ValueAct analyst warned: '$TSLA India will be even less competitive and profitable than Tesla China, which is getting clobbered.' $TSLA India will be even less competitive and profitable than Tesla China which is getting clobbered — Yaman Tasdivar (@ValueAnalyst1) July 11, 2025 Tesla's launch in India comes at a precarious time. The company is under pressure to reset the narrative, reignite sales, and reassure investors. Entering a new, massive market is a clear bet on growth. But it also raises questions about profitability, supply chain logistics, and whether Tesla can still lead the global EV race. For now, the launch of Tesla's first showroom in Mumbai marks the start of a new chapter. The real test will be whether India becomes Tesla's next big success story, or just another headline in a rough year for Musk's empire.
Yahoo
3 days ago
- Automotive
- Yahoo
NIO (NYSE:NIO) Reports 17.5% Year-Over-Year Rise In June 2025 Vehicle Deliveries
NIO reported a significant 11% share price increase last week following its announcement of robust delivery results for June 2025. The company delivered 24,925 vehicles, a 17.5% year-over-year rise, contributing to a strong second-quarter performance with a total of 72,056 vehicles delivered. This positive news regarding vehicle deliveries may have added weight to the broader market trends, despite the overall market performance remaining flat over the same period. Such robust figures from NIO might have bolstered investor confidence in the company's ability to achieve further growth in a generally stable market context. Every company has risks, and we've spotted 1 weakness for NIO you should know about. We've found 17 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. The recent announcement of NIO's 17.5% year-over-year increase in vehicle deliveries for June 2025, with 24,925 units delivered, signals a promising boost in operational performance that aligns well with the company's expansion plans. This development might impact investors' perception positively and suggests potential future revenue growth. However, over the past year, NIO's total return, including share price and dividends, was a decline of 19.92%. Compared to the US market, which returned 13%, and the US Auto industry, which delivered 22.7% growth over the same period, NIO's performance has been subpar, pointing to potential challenges the company may face amidst rising competition. The company's share price is currently at US$4.24, which falls short of the consensus analyst price target of US$5.08, reflecting a 16.5% higher potential. This discrepancy suggests that analysts anticipate further upside potential if current forecasts materialize. However, NIO remains unprofitable with earnings forecast to improve but not reach profitability in the next three years. Analysts expect revenue growth of 18.33% annually, although this is slower than the aggressive target of 27.0% growth assumed under some scenarios. These revenue forecasts, alongside efforts to optimize supply chains and expand globally, will be critical in assessing future share price movements compared to the target. According our valuation report, there's an indication that NIO's share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:NIO. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Time of India
4 days ago
- Climate
- Time of India
Goa gets 50 inches of rainfall this season as monsoon stays weak
Panaji: Goa received 50 inches of rainfall so far this season, reaching the milestone within 40 days. A total of 1,271.2mm of average rainfall was recorded in Goa from June 1 until 8.30 am on Friday. 'Monsoon has been generally weak except for a couple of extreme rainfall events in June and July. There is a deficit in monsoon this season by 1% compared to the all-India excess, which is at 12%,' said meteorologist and retired NIO scientist Ramesh Kumar. 'Even though the onset was in May this year, the monsoon has not been up to the mark. In July especially, except for July 2, the monsoon season has been weak to normal over Goa,' he said. Except for three rain gauge stations in Sout IMD issues red alert for Goa h Goa—Dabolim (865.4mm), Margao (978.3mm), and Mormugao (795.5mm)—all other stations have crossed the 1,000mm-mark in seasonal total, with Dharbandora already inching towards the 2,000mm-mark with 1,928mm of seasonal total rainfall recorded to date. The India Meteorological Department (IMD) has issued a yellow alert for Goa from July 13 to 15, warning of heavy rainfall likely at isolated places across the state during this period. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo According to the forecast, light to moderate rainfall accompanied by winds of 30-40 kmph, gusting up to 50 kmph, is very likely over North and South Goa districts over these three days. The IMD has also cautioned that squally weather with wind speeds of 40-50 kmph, gusting up to 60kmph, is expected to prevail over many parts of the South Maharashtra–Goa coast from July 13 to 15. Fishermen have been advised not to venture into the sea along the affected coastal areas during this period due to rough sea conditions and the risk of strong winds.
